In a randomized clinical trial, a statistic that measures the proportion of treatment effect on the primary clinical outcome that is explained by the treatment effect on a surrogate outcome is a useful concept. We investigate whether a statistic proposed to estimate this proportion can be given a causal interpretation as defined by models of counterfactual variables. For the situation of binary surrogate and outcome variables, two counterfactual models are considered, both of which include the concept of the proportion of the treatment effect, which acts through the surrogate. In general, the statistic does not equal either of the two proportions from the counterfactual models, and can be substantially different. Conditions are given for wh...
In the context of treatment effect estimation, this paper proposes a new methodology to recover the ...
The validation of surrogate endpoints has been studied by Prentice, who presented a definition as we...
Two paradigms for the evaluation of surrogate markers in randomized clinical trials have been propos...
Abstract Background The counterfactual or potential outcome model has become increasingly standard f...
To identify the appropriate action to take, an intelligent agent must infer the causal effects of ev...
In this paper, we present statistical simulation techniques of interest in substantial interpretatio...
A surrogate end point is often used to evaluate the effects of treatments or exposures on the true e...
Randomized clinical trials with rare primary endpoints or long duration times are costly. Because of...
This paper defends the claim that counterfactuals with certain features play a central role in causa...
A central question in the assessment of benefit/harm of new treatments is: how does the average outc...
We develop methods for estimation, inference and optimization of causal effects from observational d...
Summary. Inference on treatment efiects in a pretest-posttest study is a routine objective in medici...
Much research in the social and health sciences aims to understand the causal relationship between a...
Summary. We define a surrogate end point as a measure or indicator of a biological process that is o...
The relationship between association and surrogacy has been the focus of much debate in the surrogat...
In the context of treatment effect estimation, this paper proposes a new methodology to recover the ...
The validation of surrogate endpoints has been studied by Prentice, who presented a definition as we...
Two paradigms for the evaluation of surrogate markers in randomized clinical trials have been propos...
Abstract Background The counterfactual or potential outcome model has become increasingly standard f...
To identify the appropriate action to take, an intelligent agent must infer the causal effects of ev...
In this paper, we present statistical simulation techniques of interest in substantial interpretatio...
A surrogate end point is often used to evaluate the effects of treatments or exposures on the true e...
Randomized clinical trials with rare primary endpoints or long duration times are costly. Because of...
This paper defends the claim that counterfactuals with certain features play a central role in causa...
A central question in the assessment of benefit/harm of new treatments is: how does the average outc...
We develop methods for estimation, inference and optimization of causal effects from observational d...
Summary. Inference on treatment efiects in a pretest-posttest study is a routine objective in medici...
Much research in the social and health sciences aims to understand the causal relationship between a...
Summary. We define a surrogate end point as a measure or indicator of a biological process that is o...
The relationship between association and surrogacy has been the focus of much debate in the surrogat...
In the context of treatment effect estimation, this paper proposes a new methodology to recover the ...
The validation of surrogate endpoints has been studied by Prentice, who presented a definition as we...
Two paradigms for the evaluation of surrogate markers in randomized clinical trials have been propos...